Home / Catalogue/ Metabolic/ Tirzepatide

MetabolicIn StockSubQ injection

Tirzepatide

Acylated peptide · GIP/GLP-1 dual agonist · 39 amino acids

Half-life

~5d

After administration

Delivery Method

SubQ injection

Route of administration

Storage (Lyophilised)

12-24 months

room temp ≤30°C for up to 21 days

Storage (Reconstituted)

4–6 weeks

Refrigerate at 2-8C

Known For

Dual GLP-1/GIP agonist. FDA-approved for type 2 diabetes (Mounjaro) and weight loss (Zepbound). Powerful appetite suppression, blood sugar regulation, and fat loss. One of the most effective weight loss compounds available.

Mechanism of Action

Dual GIP/GLP-1 agonist — mimics 2 gut hormones to reduce appetite, slow gastric emptying, improve insulin

Body vs. External Supply

🔴 Exogenous (replaces natural)

Brand / Trade Names

Mounjaro® (diabetes) Zepbound® (weight loss) Manufacturer: Eli Lilly

Typical Research Dosage

Titrate: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg weekly. Increase every 4 weeks. SubQ once weekly.

Vial Duration Guide

10mg vial: ~4-8 weeks depending on dose phase. At 5mg/wk = 2 weeks per vial.

Recommended Vial Size

★ 10mg or 15mg vials At 2.5-5mg/wk (early titration), 10mg lasts 2-4 weeks ✓. At 10-15mg/wk maintenance, 15mg = 1-1.5 weeks ✓. Avoid 30mg+ unless at high maintenance doses.

Time to Effects

EARLY: 1-2 weeks FULL: 12-20 weeks Week 1-2: Appetite suppression noticeable almost immediately, even at lowest dose. Mild nausea common (this IS the drug working). Week 2-4: Measurable weight loss begins (1-2kg). Reduced food noise and cravings. Week 4-8: Significant weight loss visible (3-5%+ body weight). Blood sugar improvements measurable on blood work. Week 12-20: Approaching maximum effect at maintenance dose. 15-22% total body weight loss in clinical trials at 20-24 weeks. Minimum commitment: 12 weeks to properly assess. Most continue 6-12+ months.

Contraindications & Do Not Combine

• Do NOT combine with Semaglutide or Retatrutide (stacking GLP-1 agonists = severe GI toxicity, no added benefit) • Do NOT combine with Survodutide or CagriSema (same class overlap) • Caution with insulin or sulfonylureas (hypoglycaemia risk)

Common Side Effects

Nausea (25-33%), diarrhoea (17-23%), vomiting (7-12%), constipation (6-11%), injection site reaction (3-5%)

Drug Interactions

Insulin/sulfonylureas (↑hypoglycaemia risk), oral contraceptives (delayed absorption), oral medications (slowed gastric emptying affects all oral drug absorption)

Reversibility

Weight regain likely over 12-18 months off treatment. SURMOUNT-4 showed ~14% regain after 36wk withdrawal. No permanent metabolic damage.

Key Peer-Reviewed References

All studies are published in indexed journals unless otherwise noted.

• Jastreboff et al. (2022) SURMOUNT-1 Phase 3 Trial. NEJM 387(3):205-216. DOI: 10.1056/NEJMoa2206038 • Aronne et al. (2025) SURMOUNT-5 (tirz vs sema). NEJM 393(1):26-36. DOI: 10.1056/NEJMoa2416394 • FDA Approved: Mounjaro (2022, T2D), Zepbound (2023, obesity) • ClinicalTrials.gov: NCT04184622

Research Disclaimer

Almost all data is preclinical (animal or in-vitro). No large-scale randomised controlled human trials are available for most compounds on this catalogue. This information is provided for research reference only.

Storage Requirements

Refrigerate 2-8°C before first use. After first use: room temp ≤30°C for up to 21 days. Do not freeze.

State	Condition	Duration
Lyophilised (sealed)	room temp ≤30°C for up to 21 days	12-24 months
Reconstituted	2-8C	4–6 weeks

Reconstitution Note

Reconstitute with bacteriostatic water (BAC water). Do not shake vigorously -- swirl gently to dissolve. Inject BAC water slowly down the side of the vial to avoid denaturing the peptide.

Video Resources

Tirzepatide discussed by researchers & practitioners

Independent educational content from researchers, clinicians, and science communicators. Not affiliated with Pepnerd — provided as supplementary reading.

Educational resources only. The videos above are independent third-party content from researchers, clinicians, and science communicators. Pepnerd is not affiliated with any of these creators and does not endorse or make any claims based on their content. All products are sold strictly for in-vitro scientific research.

Select Vial Size

$50.00 per vial

Submit Your Test Results →

Quick Reference

Half-life	~5 days (t½ 5.0d)
Delivery	SubQ injection
Typical dose	2.5mg
Storage (lyoph.)	room temp ≤30°C for up to 21 days
Storage (recon.)	4–6 weeks
Endogenous?	Exogenous (replaces natural)
Suppression	None known
WADA	Not listed (S0 risk if misused)
FDA status	Approved (Mounjaro/Zepbound)

Your cart is empty